medigraphic.com
ISSN 0035-0052 (Print)

2023, Number 5

<< Back Next >>

Rev Mex Pediatr 2023; 90 (5)

Effectiveness and safety of oseltamivir suspension in pediatric patients with influenza or influenza-like illness

Vázquez-Narváez JA, Rochín-Kobashi IA, García-Robles MB, Delgado-Roche L

Language: Spanish
References: 12
Page: 176-179
PDF size: 249.95 Kb.


ABSTRACT

Introduction: oseltamivir is a potent inhibitor of the neuraminidase of the influenza virus, which shortens the duration of influenza symptoms. Objective: to describe the clinical outcome of using oseltamivir suspension in children with influenza or influenza-like illness. Material and methods: clinical, observational, prospective, and multicenter study. Population: children aged two to 12 years diagnosed with influenza or influenza-like illness who received oseltamivir suspension (Seltaferon®) for five days. The outcome measures were clinical evolution (assessed by CARIFS scale) and frequency of adverse events (AEs). Results: 35 patients were included, with a mean age of 5.2 ± 2.7 years. By day 5, 32 patients had clinical improvement; Regarding safety, there were eight patients in whom 18 AEs were recorded, which were mild or moderate. Conclusions: oseltamivir suspension is effective and safe in pediatric population with influenza.


REFERENCES

  1. Krammer F, Smith GJD, Fouchier RAM, Peiris M, Kedzierska K, Doherty PC et al. Influenza. Nat Rev Dis Primers. 2018; 4(1): 3.

  2. Uyeki TM, Hui DS, Zambon M, Wentworth DE, Monto AS. Influenza. Lancet. 2022; 400(10353): 693-706.

  3. Dirección General de Epidemiología. Informe Semanal de Enfermedad Respiratoria Viral. 2022 [Consulta 10 enero 2023]. Disponible en: https://www.gob.mx/cms/uploads/attachment/file/788739/INFLUENZA_OVR_SE52_2022.pdf

  4. Sur M, Lopez MJ, Baker MB. Oseltamivir. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 [Consulta 10 enero 2023]. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK539909/

  5. Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001; 20(2): 127-133.

  6. Fry AM, Goswami D, Nahar K, Sharmin AT, Rahman M, Gubareva L et al. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. Lancet Infect Dis. 2014; 14(2): 109-118.

  7. Fischer JB, Prasad PA, Coffin SE, Alpern ER, Mistry RD. Canadian acute respiratory illness and flu scale (CARIFS) for clinical detection of influenza in children. Clin Pediatr (Phila). 2014; 53(12): 1174-1180.

  8. FDA. Tamiflu, información para prescribir. [Consulta 10 enero 2023] Disponible en: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021087s062lbl.pdf

  9. García Robles MB, Pérez de Léon MP, Rosete Reyes A, González de la Parra M. Seguridad del tratamiento con oseltamivir en pacientes ambulatorios mexicanos con influenza y enfermedad tipo influenza. Enf Infec Microbiol. 2020; 40(3): 81-86.

  10. eHealthMe. Tamiflu and loss of appetite – a phase IV clinical study of FDA data. [Consulta 10 enero 2023] Disponible en: https://www.ehealthme.com/ds/tamiflu/loss-of-appetite/

  11. Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ et al. Neuraminidase inhibitors for preventing and treating influenza in adults and children. Cochrane Database Syst Rev. 2014; 2014 (4): CD008965.

  12. Tagarro A, Cruz-Cañete M, Otheo E, Launes C, Couceiro JA, Pérez C et al. Oseltamivir for the treatment of influenza in children and adolescents. An Pediatr (Engl Ed). 2019; 90(5): 317.e1-317.e8.




2020     |     www.medigraphic.com